Print
|
Close
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Active:
Yes
Cancer Type:
Breast Cancer
NCT ID:
NCT02926690
Trial Phases:
Phase I
Protocol IDs:
OTS1070103 (primary)
NCI-2017-00301
Eligibility:
18 Years and older, Male and Female
Study Type:
Treatment
Study Sponsor:
OncoTherapy Science, Inc.
NCI Full Details:
http://clinicaltrials.gov/show/NCT02926690
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of OTS167
administered via oral capsule (PO) to patients with relapsed/refractory locally advanced
or metastatic breast cancer.
Treatment Sites in Georgia
Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu
**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts...
Click here to learn more about clinical trials
.